Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Hydrogen/deuterium exchange coupled to mass spectrometry (HX-MS) is a valuable technique for analyzing the structural features and dynamic properties of individual proteins and large protein complexes. HX-MS can be used to study a wide range of structural properties including protein folding, ligand binding and allostery, and epitope mapping in the development of therapeutic antibodies. However, HX-MS is not routinely used in protein structure analysis because of data analysis challenges that limit its throughput and scope.
In this GEN webinar, Dr. David Schriemer (University of Calgary) will present an innovative approach for applying HX-MS to protein analysis in biotherapeutics development. He will demonstrate a data independent acquisition-based HX-MS workflow that significantly reduces analysis times, enables the study of larger datasets, and paves the way for a standardized strategy for protein structure analysis. Dr. Schriemer will show how HX-MS can rapidly characterize drug-binding interactions using a 500-kDa mammalian kinase using affinity pulldowns.
David Schriemer, Ph.D., Professor, University of Calgary
Dave Schriemer is an academic and entrepreneur. He graduated with degrees in organic chemistry and bioanalytical chemistry and received further training in biochemistry during postdoctoral work. He was the founder of INH Technologies Inc., a biotech startup in Calgary, and served as a Research Director in MDS Proteomics Inc. before joining the Department of Biochemistry & Molecular Biology at the University of Calgary in 2001. Dr. Schriemer’s laboratory maintains a basic research program in integrative structural biology of complex systems, incorporating novel proteomics technologies, reagent development and computational methods. Dr. Schriemer has been a Canada Research Chair in Chemical Biology and a Senior Scholar of the Alberta Heritage Foundation for Medical Research. He served as the director of the SAMS Centre for Proteomics until 2017, is currently Chief Science Officer and Director of Nepetx LLC (a drug discovery company) and is establishing a scientific software development company.
* Required field
To learn more about our work in HDX-MS, visit Hydrogen Deuterium Exchange HDX Protein Structure MS.